Relationship between rheological properties, in vitro release and in vivo equivalency of topical formulations of diclofenac.


Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
15 Dec 2019
Historique:
received: 09 07 2019
revised: 27 09 2019
accepted: 30 09 2019
pubmed: 13 11 2019
medline: 21 4 2020
entrez: 13 11 2019
Statut: ppublish

Résumé

Determination of bioequivalence remains a challenge in generic topical drug development. To support pharmacokinetic studies, strategies to demonstrate microstructure sameness of the products being compared include in vitro evaluations, such as the comparison of rheological properties, droplet size and in vitro release rates. Nevertheless, defining the appropriate acceptance range to consider equivalence between test and reference formulation is complex. To shed more light into this issue, in vitro release and rheological properties were compared to in vivo bioequivalence data (systemic blood measurements within a clinical trial) after topical application of a single dose. Test and reference formulations of diclofenac diethylamine emulgels were evaluated. While the test formulation met the requirements for equivalence in both the in vivo bioequivalence and in vitro release study, the rheological properties were considered equivalent depending on the criteria used. The 90% confidence interval of the ratios between geometric mean values of both formulations were within the limits of 75-133%, but outside the 90-111% limit under discussion in the scientific community. Altogether these data indicate that differences beyond ±10% between rheological parameters of test and reference formulation might not translate into meaningful release nor bioavailability divergence.

Identifiants

pubmed: 31715355
pii: S0378-5173(19)30800-2
doi: 10.1016/j.ijpharm.2019.118755
pii:
doi:

Substances chimiques

Diclofenac 144O8QL0L1

Types de publication

Clinical Trial, Phase I Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

118755

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

María Pleguezuelos-Villa (M)

Departamento de Farmacia y Tecnología Farmacéutica y Parasitología, Facultad de Farmacia, Universitat de València, Av. Vicente Andrés Estelles s/n, Burjassot, Valencia, Spain; Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València & Universitat de València, Valencia, Spain.

Matilde Merino-Sanjuán (M)

Departamento de Farmacia y Tecnología Farmacéutica y Parasitología, Facultad de Farmacia, Universitat de València, Av. Vicente Andrés Estelles s/n, Burjassot, Valencia, Spain; Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València & Universitat de València, Valencia, Spain.

Mª Jesús Hernández (MJ)

Departament de Fisica de la Terra i Termodinàmica, Universitat de València, Av. Vicente Andrés Estelles s/n, Burjassot, Valencia, Spain.

Amparo Nácher (A)

Departamento de Farmacia y Tecnología Farmacéutica y Parasitología, Facultad de Farmacia, Universitat de València, Av. Vicente Andrés Estelles s/n, Burjassot, Valencia, Spain; Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València & Universitat de València, Valencia, Spain.

Daniel Peris (D)

Pharmacokinetics and Clinical Affairs Department, Strategy and Development Area, Kern Pharma S.L., Calle Venus 72, Terrassa, Barcelona, Spain.

Irene Hidalgo (I)

Pharmacokinetics and Clinical Affairs Department, Strategy and Development Area, Kern Pharma S.L., Calle Venus 72, Terrassa, Barcelona, Spain.

Lluís Soler (L)

Formulation and Late Scale Development Department, Strategy and Development Area, Kern Pharma S.L., Calle Venus 72, Terrassa, Barcelona, Spain.

Marta Sallan (M)

Formulation and Late Scale Development Department, Strategy and Development Area, Kern Pharma S.L., Calle Venus 72, Terrassa, Barcelona, Spain.

Virginia Merino (V)

Departamento de Farmacia y Tecnología Farmacéutica y Parasitología, Facultad de Farmacia, Universitat de València, Av. Vicente Andrés Estelles s/n, Burjassot, Valencia, Spain; Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València & Universitat de València, Valencia, Spain. Electronic address: Virginia.Merino@uv.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH